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Tissue Doppler imagingAbstract Background: Reperfusion injury limits the beneﬁcial effects of primary percutaneous
coronary intervention (PCI) in the setting of acute myocardial infarction (AMI). Adenosine limits
reperfusion injury in animal models.
Objective: Is to study the effects of high-dose intracoronary adenosine administration in the setting
of primary PCI on coronary blood ﬂow and regional left ventricular function.
Methods: Sixty patients with a deﬁnite diagnosis of ST elevation AMI within 6 h from the onset of
chest pain were randomly allocated to receive adenosine (6 mg) or saline placebo (on a 1:2 ratio) as
an adjunct to primary PCI with assessment of TIMI ﬂow, TIMI myocardial blush grade (MBG),
and occurrence of no-reﬂow. Systolic (S) wave velocity was recorded at the mitral annulus in the
territory of the infarct related artery using pulsed-wave tissue Doppler within 24 h from admission
and one week after PCI.
Results: Both groups showed no signiﬁcant difference in terms of age, sex, risk factors, infarct loca-
tion, and distribution of coronary artery disease. The adenosine group showed a higher incidence of
TIMI III ﬂow (95% vs. 65%, p< 0.03), a higher incidence of MBG 2-3 (95% vs. 67.5%,
290 K. Darahim et al.p< 0.007), and a lower incidence of no-reﬂow (10% vs. 45%, p< 0.006). Only in the adenosine
group, there was a signiﬁcant improvement in the annular pulsed tissue Doppler S wave velocity
at the infarct-related territory at day-7 (p< 0.01).
Conclusion: High-dose adenosine administration in the setting of primary PCI improves myocar-
dial perfusion and regional left ventricular systolic function.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.1. Introduction
Early reperfusion of the ischemic myocardium by thrombolytic
agents is effective in reducing mortality from acute myocardial
infarction. However, better results, including further reduction
in mortality and recurrence of ischemia, can be achieved with
direct percutaneous transluminal coronary angioplasty.1
Unfortunately reperfusion is followed by morphological
and functional changes that result in tissue damage known
as reperfusion injury.2 Reperfusion injury results from several
complex and interdependent mechanisms that involve the pro-
duction of reactive oxygen species, alterations in intracellular
calcium handling, endothelial cell dysfunction, altered myocar-
dial metabolism, and activation of neutrophils, platelets and
complement. Reperfusion injury is manifested as stunned myo-
cardium, reversible microvascular injury, and lethal myocyte
necrosis.3
Adenosine has been studied extensively as a cardioprotec-
tive agent. It antagonizes many of the biochemical and physi-
ological mechanisms implicated in the ischemia reperfusion
injury. It has been shown to replenish high energy phosphate
stores in endothelial cells and myocytes, to inhibit oxygen free
radical formation, to inhibit neutrophil activity, to participate
in myocardial ischemic preconditioning, and to improve
microvascular function,4 thereby reducing post-ischemic ven-
tricular dysfunction, myocyte necrosis and apoptosis, and in-
farct size.5 An intracoronary bolus of adenosine 30–60 lg is
recommended for prevention and treatment of no-reﬂow by
the ESC guidelines for the treatment of STEMI (class IIb; level
of evidence C).6 A small open-label clinical study has shown
that intracoronary administration of 4 mg of adenosine is safe
in patients with acute myocardial infarction, with favorable ef-
fects on TIMI ﬂow grade, incidence of no-reﬂow, left ventric-
ular function, and clinical course.7
Encouraged by this data, we thought of studying the effects
of high-dose intracoronary adenosine immediately before ini-
tial balloon inﬂation on coronary blood ﬂow and regional left
ventricular systolic function in acute myocardial infarction. In
the design of the present study, we attempted to address some
of the methodological limitations of earlier trials. First, we
used tissue Doppler imaging (TDI) to assess the improvement
in regional LV systolic function because it offers an objective
measure to quantify regional LV function.8 Second, we admin-
istered the study drug sub-selectively to the ischemic myocar-
dium. Third, we used a very high dose of adenosine, and
last, we administered the intracoronary adenosine before ini-
tial balloon dilatation.1.1. Objectives
The aim of this work is to study the effects of high-dose intra-
coronary adenosine administration in the setting of primaryPCI on the coronary blood ﬂow and regional left ventricular
systolic function.
1.2. Methodology
1.2.1. Study population
This study included 60 patients referred to the Ain Shams Uni-
versity Hospital for primary PCI within 6 h from the onset of
acute myocardial infarction.
Inclusion criteria were symptoms of chest pain lasting at
least 20 min, not relieved by sublingual nitrates, and an ECG
showing ST segment elevation >0.1 mV in two or more limb
leads or >0.2 mV in two or more contagious precordial leads,
or presumed new left bundle branch block. Presentation
should be within 6 h from the onset of chest pain. The patient
must have native coronary artery disease with TIMI ﬂow from
0–2.
Exclusion criteria were hypersensitivity or contraindication
to heparin, aspirin, or contrast media, receiving thrombolytic
therapy, severe asthma, high grade AV block, or cardiogenic
shock (systolic blood pressure (SBP) <80 mmHg sustained
for >30 min, unresponsive to ﬂuids, or SBP <100 mmHg
with vasopressors and/or requirement for intra-aortic balloon
pump). Patients with spontaneous reperfusion (TIMI III ﬂow
at diagnostic coronary angiography) were excluded.
1.2.1.1. Study design. Eligible patients were randomly allocated
(1:2) to receive adenosine or saline placebo. The study was ap-
proved by the medical ethics committee of our institution and
all patients gave an informed consent before the procedure.
2. Methods
2.1. Standard 12-leads electrocardiogram
The 12-lead ECG obtained on admission and after reperfusion
was investigated for the degree of ST segment deviation from
isoelectric line, which was measured manually to the nearest
0.5 mm in every lead at 0.08 s after J-point using preceding
TP segment as a baseline. The magnitude of ST segment reso-
lution was expressed as a percentage of initial ST elevation.
2.2. Invasive procedure
All patients received heparin (5000 IU), aspirin (150 mg), and
clopidogrel (300 mg). The patients were subjected to diagnostic
coronary angiogram through a femoral approach. PCI was
performed using the standard technique for the culprit lesion
only. After giving an additional bolus of heparin (5000 units),
the obstruction of the infarct related artery was crossed with a
0.014 inch guidewire. An over-the-wire balloon was positioned
at the level of the obstruction. The wire was pulled out, and
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balloon to conﬁrm positioning of the balloon tip downstream
of the obstruction and to assess the patency of the distal vessel.
The balloon was inﬂated, and either adenosine (6 mg in 2 ml
0.9% saline) or saline (2 ml of 0.9% saline) was hand injected
over 30 s into the distal vessel. The guide wire was then re-ad-
vanced into the distal vessel and the balloon was deﬂated.
Stenting of the dilated coronary segment was performed, un-
less there is contraindication (dense deep calciﬁcation, very
large thrombus burden, and severe proximal tortuosity). The
use of glycoprotein IIb/IIIa inhibitors was left to the discretion
of the operator. Final angiogram was taken 15 min after com-
pletion of the dilatation. The procedure was considered suc-
cessful if there were adequate stent expansion, less than 15%
residual stenosis, absence of edge dissection, and absence of
instent thrombosis.
2.3. Angiographic analysis
Coronary angiograms obtained before and after primary PCI
were reviewed by two experienced operators blinded to
treatment allocation and clinical data. On the initial angio-
gram and on the angiogram after stenting, TIMI ﬂow grade
was assessed according to the TIMI study criteria.9 Corrected
TIMI frame count (CTFC) and TIMI myocardial blush
grade (MBG) were assessed after stenting as described
previously.10,11
No reﬂow was diagnosed when there was reduction of 1 or
more in the TIMI grade in the ﬁnal angiogram compared to
the post PCI angiogram, or patients with TIMI 3 ﬂow and
low TIMI myocardial perfusion grade (0–1).11
2.4. Biochemical data
Creatine kinase (CK) and CK-MB levels were assessed every
8 h on the ﬁrst day of admission and then, daily till discharge.
2.5. Left ventricular function assessment
2.5.1. 2-D echocardiography
Left ventricular (LV) ejection fraction was evaluated by 2D
echocardiography within 24 h from admission using a Vivid-
ﬁve echo machine, with a 2.5 MHz transducer. LV ejection
fraction was estimated by the Simpson’s modiﬁed biplane
method. Resting segmental wall motion was assessed in the
standard imaging views: parasternal long axis ± apical long
axis, apical 2-chamber, and apical 4-chamber. LV wall was di-
vided into 16 segments. The wall motion of each segment was
examined and scored according to the modiﬁcation12 of the
recommendation of the American Society of Echocardiogra-
phy.13 Images were analyzed by 2 experienced observers
blinded to the angiographic data.
2.5.2. Pulsed wave tissue Doppler
Tissue Doppler imaging (TDI) was performed using a Vivid-5
echo machine. The machine was switched to TDI mode, result-
ing in lowering of the velocity range to encode myocardial
velocities. Pulsed tissue Doppler samples were recorded from
six different locations with the sample volume placed at the le-
vel of the mitral annulus (posterior septum, lateral, anterior,inferior, anterior septum, and posterior), using the apical 4-
chamber view, apical 2-chamber view and the apical long-axis
view. Peak systolic (S) annular velocities were recorded in the
walls with resting wall motion abnormality in the territory of
the infarct related artery. S wave velocities obtained within
24 h of admission were compared with those obtained after
one week to detect changes in the regional systolic function.
2.6. Statistical analysis
The data were statistically analyzed using the Statistical Pack-
age for Social Sciences (SPSS) software version (9). Categorical
variables are presented as frequency values and proportions
and were compared by Chi square test. Continuous normally
distributed variables are presented as mean values and stan-
dard deviations. Paired-sample t-test was used to compare con-
tinuous variables. A p value <0.05 (2-tailed) was considered
signiﬁcant and a p value <0.01 was considered highly
signiﬁcant.3. Results
This study included 60 patients (adenosine group, n= 20; pla-
cebo group, n= 40) referred to the coronary care unit of the
Ain Shams university hospital with acute ST elevation myocar-
dial infarction, within 6 h from the onset of the chest pain, for
primary PCI.
The baseline clinical and angiographic characteristics of the
study population were similar in both groups; however, the pa-
tients in the placebo group presented earlier (Table 1).
3.1. Invasive procedure
The angioplasty procedure was done targeting only the culprit
lesion in the infarct-related artery. No patients had any degree
of AV block in their presenting ECG, so transient transvenous
pacing was not done in any patient before starting PCI. Only
one patient (1.67%) with inferior AMI developed a junctional
rhythm at a rate of 40 beat/min after reperfusion and was asso-
ciated with marked hypotension; thus, the insertion of a tem-
porary pacemaker wire in the RV apex was deemed
necessary. The wire was removed after 24 h. The injection of
adenosine or saline in the distal coronary bed was well toler-
ated and free of side effects. No patients complained of wors-
ening of chest pain, or had hemodynamic instability. Transient
sinus bradycardia occurred in two patients (3.3%).
Stenting of the culprit lesion was done in 18 patients (90%)
of the adenosine group, and in 36 patients (90%) of the pla-
cebo group. PTCA was performed in 6 patients (10%) without
stenting (small infarct-related artery, very large thrombus bur-
den, successful angioplasty of total in-stent occlusion). Tiroﬁ-
ban was used in 8 patients (40%) of the adenosine group and
20 patients (50%) of the placebo group. No statistically signif-
icant differences were noted among the two treatment groups
regarding the angioplasty procedure.
3.2. Angiographic results (Table 2)
TIMI ﬂow: the percentage of patients who achieved TIMI III
ﬂow in the ﬁnal angiogram was signiﬁcantly higher in the
Table 1 Baseline clinical and angiographic characteristics of the study group.
Adenosine group
(n= 20)
Placebo group
(n= 40)
p value
Age 51.2 ± 9.1 53.4 ± 11.3 NS
Sex
Male 14 (70%) 30 (75%) NS
Female 6 (30%) 10 (25%)
Risk factors
Smoking 14 (70%) 24 (60%) NS
Diabetes 7 (35%) 14 (35%)
Hypertension 7 (35%) 18 (45%)
Dyslipidemia 1 (5%) 6 (15%)
Family history 1 (5%) 0
Previous MI
Anterior 2 (10%) 4 (10%) NS
Inferior 0 4 (10%)
Site of MI
Anterior 16 (80%) 23 (57.5%) NS
Inferior 4 (20%) 14 (35%)
Lateral 0 3 (7.5%)
Infarct related artery
Left anterior descending 16 (80%) 23 (57.5%) NS
Right coronary 3 (15%) 12 (30%)
Left circumﬂex 1 (5%) 1 (2.5%)
Obtuse marginal 0 3 (7.5%)
Posterior descending 0 1 (2.5%)
Coronary aﬀection
Left anterior descending 18 (90%) 29 (72.5%) NS
Right coronary 7 (35%) 18 (45%)
Diagonal 0 1 (2.5%)
Left circumﬂex 2 (10%) 6 (15%)
Obtuse marginal 2 (10%) 6 (15%)
Hemodynamic
Systolic BP 112.5 ± 19.7 123 ± 23.1 NS
Heart rate 80.7 ± 15.1 81.9 ± 16.9
Mean time to PCI in hours 4.7 ± 1.2 3.75 ± 1.33 0.009
Data are expressed as a mean ± standard deviation or a number (%). BP = blood pressure, PCI = percutaneous coronary intervention.
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65%, p< 0.05).
TIMI frame count: in comparison to the placebo group, the
adenosine group had a signiﬁcantly lower corrected TIMI
frame count (11.5 ± 3.1 frames vs. 23.1 ± 9.8 frames,
p< 0.0001).
TIMI myocardial blush grade (MBG): the percentage of pa-
tients who achieved MBG II-III was signiﬁcantly higher in the
adenosine group compared to the placebo group (95% vs.
67.5%, p< 0.01).
No-reﬂow phenomenon: no-reﬂow was signiﬁcantly lower in
the adenosine group compared to the placebo group (10% vs.
45%, p< 0.006)
3.3. Left ventricular function assessment
3.3.1. Global LV Function
LV Ejection fraction for all patients was 46.8 ± 7.14%. No
statistically signiﬁcant difference was noted between the 2
treatment groups (45.4 ± 7.3% vs. 47.5 ± 7.03%, p> 0.05).3.3.2. Pulse-tissue Doppler ﬁndings
S wave velocity was recorded (in cm/s) at the mitral annulus in
the territory of the infarct-related artery. The velocities were
recorded in 50 patients out of the studied group (83%). The
placebo group did not show any signiﬁcant improvement in
the S wave velocities at any of the walls recorded at day-7.
On the other hand, signiﬁcant improvement in the S wave
velocity was noted at day-7 at the 6 walls in the adenosine
group (p< 0.01). These data are summarized in Table 3 and
Figs. 1 and 2.
3.4. In-hospital clinical course
Eighteen patients had complete ST resolution (P70%) in the
adenosine group, compared to 22 patients in the placebo group
(90% vs. 55%, p< 0.01). The in-hospital clinical course was
uneventful for most of the 60 patients. Only 1 patient
(1.67%) had a stormy post PCI course and died after 14 days.
No statistically signiﬁcant differences were noted between the 2
treatment groups as regards the hospital events (Table 4).
Table 2 Angiographic outcome of the studied group.
Adenosine group (No = 20) Placebo group (No = 40) p value
TIMI grade
 III 19 (95%) 26 (65%) 0.03
 II 1 (5%) 12 (30%)
 I 0 2 (5%)
MBG
 III 17 (85%) 16 (40%) 0.007
 II 17 (85%) 11 (27%)
 I 1 (5%) 3 (7.5%)
 0 0 10 (25%)
CTFC 11.5 ± 3.1 23.1 ± 9.8 <0.00001
No Reﬂow 2 (10%) 18 (45%) <0.006
Data are expressed as a mean ± standard deviation or a number (%).
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reperfusion, with signiﬁcantly lower peak values in the adeno-
sine group compared to the placebo group (Table 4).
4. Discussion
Early restoration of the coronary blood ﬂow is necessary to
resuscitate the myocardium. Reperfusion might salvage a
substantial amount of the jeopardized myocardium and re-
duce cardiac morbidity and mortality.3 Primary percutane-
ous coronary intervention has been proved to be more
effective than thrombolytic therapy in reducing the rates of
deaths, reinfarction, and stroke.14 Despite better outcomes
with early reperfusion for the treatment of acute ST eleva-
tion MI, morbidity and mortality from AMI to remain sig-
niﬁcant and incidence of congestive heart failure continues
to increase.15
The concept of reperfusion injury, although identiﬁed ﬁrst
in animal studies, is now recognized as a clinical phenomenon
that occurs in up to 33% of patients with AMI leading to
incomplete myocardial perfusion.16 The pathophysiology of
reperfusion injury is complex that involves the production of
reactive oxygen species, alterations in intracellular calcium
handling, microvascular and endothelial cell dysfunction, and
altered myocardial metabolism. Reperfusion injury is mani-
fested as stunned myocardium, reversible microvascular injury,
no-reﬂow, and lethal myocyte necrosis.3 The pathogenesis of
no-reﬂow is complex and involves interstitial edema, cell swell-
ing, and capillary plugging by activated neutrophils and aggre-
gated platelets.17 No-reﬂow phenomenon occurs in 29% of
patients undergoing primary PCI for ST-segment elevation
myocardial infarction (STEMI).18 No-reﬂow doubles the risk
of mortality out to 5 years.18 On multivariable analysis that
controlled for infarct size among numerous other factors,
no-reﬂow remained an independent predictor of 5-year mortal-
ity (HR 1.66; 95% CI 1.17–2.36; p= 0.004).18 The net effects
of reperfusion are usually beneﬁcial; however, there is a need
to provide better cardioprotection by strategies that prevent
its negative counterparts, and reduce the amount of necrosis
that may optimize myocardial salvage and improve functional
recovery.
Adenosine has been extensively investigated as a cardiopro-
tective agent. Through its multi-targeted actions, it has been
shown to inhibit many of the mechanisms involved in thepathogenesis of reperfusion injury.19 It was shown to reduce
infarct size, reduce intracellular lactate levels, increase ATP
production, reduce intracellular calcium load,20 reduce post-
ischemic contractile dysfunction, and preserve the post-ische-
mic coronary ﬂow reserve by neutrophil and non-neutrophil
dependent mechanisms.19
4.1. Adenosine effect on coronary blood ﬂow and the incidence of
no-reﬂow
In the design of the present study, we attempted to address
some of the methodological limitations of earlier trials. First,
we used TDI to assess the improvement in regional LV systolic
function because it offers an objective measure to quantify re-
gional LV function.8 Second, we administered the study drug
sub-selectively to the ischaemic myocardium. Third, we used
a very high dose of adenosine. Fourth, we administered the
intracoronary adenosine before initial balloon dilatation.
Fifth, we excluded patients with spontaneous reperfusion at
baseline angiography to be sure that adenosine was given be-
fore reperfusion, and last, angiographic deﬁnition of successful
reperfusion included both TIMI 3 ﬂow as well as MBG 2 or 3.
For many years, epicardial coronary ﬂow has been simply as-
sessed by the TIMI ﬂow grades.9 Despite successful recanaliza-
tion by either thrombolytic agents or PCI, a substantial
number of patients with TIMI 3 ﬂow still fail to obtain com-
plete and sustained myocardial reperfusion and remain at risk
of developing large infarcts. The so called ‘‘low-reﬂow’’ phe-
nomenon was held responsible for this observation. An open
epicardial artery without ﬂow into the myocardium predicts
complications and LV dilation.21 Therefore, angiographic def-
inition of successful reperfusion should include both TIMI 3
ﬂow as well as MBG 2 or 3.22
In this study, the adenosine treated patients showed a sig-
niﬁcantly higher incidence of having TIMI III grades in com-
parison to the placebo group signifying successful epicardial
perfusion and adequate infarct related artery patency. The per-
centage of patients with TMP 2 or 3 was also signiﬁcantly
higher in the adenosine treated patients in comparison with
the placebo group.
Clinical studies with adenosine in patients with AMI have
yielded mixed results. In agreement with our study, similar
effects of adenosine on the incidence of TIMI III ﬂow and
no-reﬂow after primary PCI were reported previously.7
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294 K. Darahim et al.Similarly, another study reported that intracoronary adeno-
sine infusion is effective in the reduction of the incidence of
no-reﬂow during PCI for AMI thus improving the outcome
of the procedure.23 Moreover, another report stated that
adenosine is effective in treatment of angiographic no-re-
ﬂow phenomenon especially when combined with nitro-
prusside.24 The corrected TIMI frame count is a
quantitative continuous variable. It is objective, reproduc-
ible, and sensitive to the ﬂow changes. It has been shown
to predict the systolic LV function at 48 h with trends to-
ward smaller endsystolic volumes and higher LV ejection
fraction with low CTFC.25 It was also associated with im-
proved 2-year survival.11 In this study, the adenosine trea-
ted patients had a signiﬁcantly lower corrected TIMI frame
count, signifying a faster ﬂow in the culprit vessel. This fast
ﬂow is related partly to the vasodilator effect of adenosine
and to the low resistance at the microcirculatory level due
to the marked attenuation of microvascular reperfusion in-
jury. The optimal method to assess successful perfusion was
studied by Giugliano et al.26 They deﬁned the complete res-
toration of reperfusion or the ‘‘trifecta’’ as the presence of
TIMI III ﬂow, MBG 3, and complete ST segment resolu-
tion (P70%). The achievement of the trifecta was associ-
ated with low rates of 30-day mortality and heart failure.
In our study, 85% of the adenosine treated patients have
achieved the trifecta compared to 40% of the placebo
group.
In the AMISTAD-II trial, conducted in patients with
anterior STEMI treated by ﬁbrinolysis or primary PCI, a
3 h intravenous infusion of adenosine did not reduce the
primary clinical endpoint.27 However, in a post hoc sub-
group analysis, a beneﬁt was seen in those reperfused with-
in 3 h, and adenosine infusion enhanced early and late
survival, and reduced the composite clinical endpoint of
death or heart failure at 6 months.28 Another study of
448 STEMI patients randomized to two bolus injections
of intracoronary adenosine (2 · 120 lg) or matching pla-
cebo after manual thrombus aspiration did not show any
difference in the primary endpoint of residual ST-segment
elevation after primary PCI.29 In addition, all secondary
endpoints (ST-segment elevation resolution, myocardial
blush grade, TIMI ﬂow after PCI, enzymatic infarct size,
and clinical outcome at 30 days) did not differ between
the treatment groups. As a possible explanation, the
authors argued that adenosine may have a maximal bene-
ﬁcial effect on ischemic myocardial injury when given be-
fore reperfusion therapy, whereas they performed
thrombus aspiration before administration of adenosine
or placebo. In a single-center, double-blind, placebo-con-
trolled clinical study, high-dose intracoronary administra-
tion of adenosine distal to the occlusion site immediately
before initial balloon inﬂation did not result in myocardial
salvage as assessed with cardiac magnetic resonance imag-
ing. TIMI ﬂow grade, TIMI frame count, myocardial
blush grade, and ST-segment resolution after primary per-
cutaneous coronary intervention were similar between
groups.30 As a possible explanation, the authors stated
that 28% of patients had limited spontaneous reperfusion
before intracoronary administration of the study drug.
Hence, in these patients, adenosine was not truly given be-
fore reperfusion.
46
8
Post septum Lateral Anterior Inferior Ant septum Posterior
Mean annular S wave velocities
Day 1
Day 7
Figure 1 Effect of adenosine on systolic tissue Doppler parameters. Statistically signiﬁcant differences were noted in the mean annular S
wave velocity at follow up at all walls compared to the initial evaluation.
4
6
8
Post septum Lateral Anterior Inferior Ant septum Posterior
Day 1
Day 7
Figure 2 Annular S wave velocity in the placebo group. No signiﬁcant improvement was noted in any of the 6 walls at follow up
compared to the initial evaluation.
Table 4 In-hospital clinical course.
Adenosine
group
(No = 20)
Placebo
group
(No = 40)
p value
Non-fatal MI 0 1 (2.5%) >0.05
Death 0 1 (2.5%) >0.05
Total CK peak in
international units
1880.3 ± 1020.4 2806 ± 1379.0 0.01
Clinical events are expressed as percentages. Metabolic data are
expressed as mean ± standard deviation.
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In our study, intracoronary adenosine administration was safe
and well tolerated by all patients with no signiﬁcant hemody-
namic effects. Transient sinus bradycardia was infrequently
noted after adenosine injections; however, serious bradycar-
dias were never encountered in this study. No AV block was
observed in any of the patients. This may be related to the slow
injection of adenosine over 30 s, and to the sympathetic drive
associated with acute MI that may counteract the effect of
adenosine on the AV node. Similar results were found in aprevious study, where prophylactic transient pacemaker was
applied to all patients, but the wire never ﬁred.7
In the present study, 6 mg of adenosine was injected safely.
In fact, one of the adenosine patients who had no-reﬂow re-
ceived additional 6 mg in an attempt to improve the coronary
ﬂow and this dose was also well tolerated. These doses are
higher than those used by previous studies, which reported
the use of 4 mg of adenosine and reported on its safety.7,30
4.3. Does adenosine really improve regional systolic LV
function?
In this study, adenosine-treated patients demonstrated signiﬁ-
cant improvement in the mean S wave velocities measured at
the six different mitral annular locations during the second
evaluation compared to the initial recordings. Similar results
on early recovery of segmental wall motion using the 2D echo-
cardiography were reported by Marzilli et al.7
To the best of our knowledge, this study is the ﬁrst in the
literature to demonstrate the effect of adenosine on myocardial
regional systolic function using tissue Doppler imaging. Be-
cause the apex is relatively stable and the mitral annular mo-
tion is almost parallel to the imaging plane in apical views,
the mitral annular motion recorded from the apical views is
taken into consideration in the evaluation of regional left ven-
tricular functions. It could provide a more accurate assessment
296 K. Darahim et al.of the changes in the systolic function of the individual seg-
ments that may overcome the relative subjectivity of 2D
echocardiography.
4.4. Limitations of the study
Our study has multiple limitations. First, the study population
was small. However, despite the small sample size, we found a
signiﬁcant improvement in myocardial ﬂow and LV regional
systolic function. Second, during the design of the study, the
authors did not consider the option of double-blind study.
Apart from the cost issue, we concluded that it was almost
impossible to blind the operators as most patients would devel-
op transient heart block and bradycardia after adenosine
administration. The arrhythmic effect could be easily observed
on the monitoring screen where the operators pay close atten-
tion to during the coronary intervention procedure. Third,
echocardiographic assessment of regional systolic function
improvement is inﬂuenced by differences in the extent of ische-
mic myocardium at baseline between the two treatment
groups. It should be noted that, MRI is the most accurate
non-invasive technique to measure the infarct size relative to
risk area. Finally, post-PCI troponin level was not measured,
yet most of the prognostic data in this setting are mainly stud-
ied with CK-MB.
5. Conclusion and clinical implications
High-dose intracoronary adenosine can be easily and safely
administrated in the setting of acute MI. High-dose
adenosine improves both TIMI ﬂow and myocardial blush
grade, reduces no-reﬂow, and improves regional LV systolic
function. In view of the small sample size included in this
report, larger clinical studies are needed to conﬁrm these
observations.Conﬂict of interest
None.
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